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Abstract
Background: Human Papillomavirus (HPV) infections have been shown to be a necessary risk factor for the
development of cervical cancer. However, HPV genotype distribution varies geographically, both in type and
relative prevalence. In order to ensure a successful introduction of available vaccines, there is the need to identify
pre-vaccination HPV genotype prevalence in Ghana and the extent of single and multiple-infections.
Methods: Paraffin-embedded cervical tissues of 256 confirmed cervical cancer cases diagnosed at the Korle-Bu
Teaching Hospital during the period January 2004 to December 2006 were selected after hematoxylin and eosin
staining and confirmation. Following a heat-proteinase K-based tissue lysis, HPV was detected and typed by a
nested-multiplex PCR assay using an E6/E7 consensus primer and type-specific primers.
Results: Of the 256 cases, 230 (89.8 %, 95 % CI 85.7–93.4 %) were positive for HPV DNA. HPV18 (47.4 %), HPV59
(42.2 %), HPV45 (37.4 %) and HPV16 (9.0 %) were the four common HPV genotypes detected. A total of 110 (47.8 %)
of the 230 HPV DNA positive tissues, were infected by a single HPV genotype while the other 120 (52.2 %) were
infected by multiple HPV genotypes. A significant association was determined between each of the following HPV
genotypes and multiple-infection; HPV18 (OR = 6.97; 95 % CI, 3.89–12.50), HPV59 (OR = 9.56; 95 % CI, 5.57–20.02) and
HPV45 (OR = 1.94; 95 % CI, 1.12–3.35).
Conclusion: The prevalence of the following high risk HPV genotypes (HPV18, HPV59, HPV45) were relatively high
among the cases of cervical cancers reported at this hospital in Ghana during the study period. Additionally, there
was a high frequency of HPV multiple-infections among these cases.
Keywords: Nested PCR, Multiplex PCR, Human Papillomavirus, Cervical cancer, Paraffin-embedded tissues, Ghana
Background
The West African region was estimated to bear the sec-
ond highest burden of cervical cancer, with a mortality
to incidence ratio of 81.2 % and cervical cancer was esti-
mated to be the most frequent cancer among women in
Ghana as at the time of this study [1]. The age standar-
dised ratio (ASR) of 39.5 per 100,000 women [1]. An
earlier study at the Korle-Bu Teaching Hospital also re-
ported that 58.3 % of gynaecological cancers seen at the
hospital in the year 2000 were cases of cervical cancer
[2]. At the same hospital, a 10 year (1991–2000) study of
cancer mortality pattern revealed that cervical cancer
was one of the four leading causes of cancer deaths (Age
Standardized Cancer Ratio of 8.74 %) in females [3].
A number of studies have shown that persistent infec-
tions with certain human Papillomavirus (HPV) geno-
types known as high risk HPV type (HPV-16, -18, -31,
-35, -39, -45, -51, -52, -56, -58, -59 and -68) are neces-
sary in the aetiology of cervical cancer. These high risk
HPV genotypes have been shown to be associated with
greater than 99.0 % of all cervical cancer cases [4–7]. Of
these high risk HPV genotypes HPV16 and HPV18 are
the two prevalent HPV types in cervical carcinoma glo-
bally and are associated with approximately 60.0 % and
10.0 % of cervical cancer cases respectively [8–10].
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However, epidemiological studies have shown a global
geographical variation in the type specific and relative
HPV prevalence among different populations; these
range between 2 and 44 % [11]. Fortunately, there are
indications of high efficacy of available vaccines against
HPV infections and a greater possibility of preventing
cervical cancer. However, it not clear how the population
specific HPV genotype distribution, extent of multiple-
infections and the HPV types involved in these
multiple-infections will change following a successful
implementation of these efficacious vaccines. Evidence
is building on the occurrence of cross protection against
non-vaccine HPVs and the possibility of the occurrence of
HPV genotype replacements among vaccinated popula-
tions. In order to determine the occurrence of such
changes, knowledge of the pre- and post-vaccination HPV
genotype distribution is very important.
However, empirical data on the overall and HPV geno-
type specific prevalence in cases of cervical cancers in
Ghana were very few at the time of this study. Addition-
ally, and in order to evaluate the potential benefits of an
introduction of HPV vaccination in Ghana, this study
was designed to detect, genotype and determine the
extent of multiple HPV infection using archival formalin-
fixed paraffin-embedded cervical tumour specimen
collected from the Pathology Department of Korle-Bu
Teaching Hospital during the years 2004–2006. For the
detection of HPV, a nested-multiplex PCR method that
had been shown to be very sensitive and specific, with de-
tection rates of between 91.8 % for cervical intraepithelial
neoplasia (CIN I) and 99.3 % for CIN III was used [12].
Method
Sample collection and DNA extraction
The Korle-Bu Teaching Hospital is one of the tertiary re-
ferral centre for persons or specimens with any form of
suspected malignancy in Ghana. Paraffin-embedded
formalin-fixed cervical tissues of women who were re-
ferred to the Pathology Department of the Korle-Bu
Teaching Hospital, Accra, between January 2004 and
December 2006 and diagnosed histologically with high
grade precursor lesion (CIN III, high grade squamous
Intraepithelial lesion (HSIL), or carcinoma in situ) or
cervical cancer (adenocarcinoma, adenosquamous car-
cinoma or any form of squamous cell carcinoma), were
selected for this study. Cases diagnosed as adenocarcin-
oma and adenosquamous were grouped together as
invasive adenocarcinoma (IAC), any form of squamous
cell carcinoma were grouped as invasive squamous cell
carcinoma (ISCC) and all forms of carcinoma in situ
were grouped as carcinoma in situ (CIS).
Each tissue block was sectioned to obtain three 9-μm
sections, each with a separate and sterile microtone
blade. The middle section was stored in a 2 mL sterile
microfuge tube for DNA extraction. The first and third
sections were stained with hematoxylin and eosin (H/E)
and examined for cancerous tissues by 2 Consultant
Pathologist. The presence of cancerous tissue in the
stained sections confirmed that the middle section used
for DNA extraction actually contained cancer tissue. 256
samples, consisting of 10 cases of carcinoma in situ
(CIS), 19 cases of invasive adenocarcinoma (IAC) and
227 cases of invasive squamous cell carcinoma (ISCC)
were found to have contain cancerous tissues and so
were used for subsequent analysis.
DNA was extracted from the 256 samples, as described
by Dabic’ et al., [13] with slight modifications. In brief,
10 μm section was incubated in 250 μL of extraction
buffer (consisting of 1 mg/mL Proteinase K in 50 mM
Tris-HCl pH 8, 1 mM EDTA and 0.5 % Tween-20) for
16 h at 56OC. The proteinase K was thereafter inactivated
by heating at 100OC for 5 min. The tubes were allowed to
cool to room temperature after which the tubes were
centrifuged at 5000xg for 5 min. The tissue lysates were
transferred for storage at -20 °C as aliquots of 70 μL.
Positive and negative controls (previously confirmed can-
cerous and non-cancerous cervical tissues respectively),
were used for the DNA extraction.
Detection and genotyping of HPV by nested-multiplex
PCR
The method and primer sets used for the nested-multiplex
PCR were as described by Soltar et al., [14] with slight
modification. Its sensitivity was as higher as that of the
MY/GP primer assay (102–101 viral copy detection) [14]
and an initial adoption of this method in our laboratory
showed it was effective for the purpose of genotyping the
high risk HPVs [15]. This assay targets the detection of 18
HPV genotypes (6/11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45,
51, 52, 56, 58, 59, 66 and 68) with a sensitivity comparable
to that of the MY/GP assay but higher than those of the
MY09-MY11 and GP5 + -GP6+ assays which amplifies the
L1 region of the HPV genome. Briefly, HPV DNA in the
lysate was amplified using a single consensus forward pri-
mer, GP-E6-3 F [GGGWG KKACT GAAAT CGGT], and
two consensus reverse primers GP-E7-5B [CTGAG
CTGTC ARNTA ATTGC TCA] and GP-E7-6B – [TCCTC
TGAGT YGYCT AATTG CTC]. The four second round
primer-cocktail-sets, as shown in Table 1, were used for the
genotyping. Both first and second round PCRs were per-
formed in a final volume of 25 μL and each PCR mixture
contained 50 mM KCl, 9 mM Tris-HCl (pH 9.0), 1 %
Triton-X100, 2.0 mM MgCl2, 0.2 mM of each dNTP, 320
nM of each of the primers and 1.25 U of Taq polymerase.
The amplifications were carried out using a thermal cycler
(Applied Biosystems 1720) with the following parameters:
For the first round PCR, using 5.0 μL or 1 μL of lysate,
an initial denaturation at 94 °C for 4 min was followed
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by 40 cycles of denaturation at 94 °C for 1 min, anneal-
ing at 40 °C for 2 min and an extension at 72 °C for
2 min. A single final extension at 72 °C for 9 min was
performed before a soaking step at 4 °C. For the second
round PCR, 2.0 μL of the first round PCR product were
used as the template DNA with each of the four cock-
tails of type specific primers for genotyping (Table 1).
The cycling parameters were as follows: an initial
Table 1 Sequences of synthetic oligonucleotide primers used for HPV genotyping
Primer cocktail HPV genotype primer Size of amplicon (bp) Sequence 5′to 3′)
Consensus primers GP-E6-3 F GGGWG KKACT GAAAT CGGT
GP-E7-5B CTGAG CTGTC ARNTA ATTGC TCA
GP-E7-6B TCCTC TGAGT YGYCT AATTG CTC
Cocktail 1 HPV16f 457 CACAG TTATG CACAG AGCTGC
HPV16r CATAT ATTCA TGCAA TGTAG GTGTA
HPV18f 323 CACTT CACTG CAAGA CATAG A
HPV18r GTTGT GAAAT CGTC GTTTT TCA
HPV31f 263 GAAAT TGCAT GAACT AAGCT CG
HPV31r CACAT ATACC TTTGT TTGTC AA
HPV59f 215 CAAAG GGGAA CTGCA AGAAA G
HPV59r TATAA CAGCG TATCA GCACC
HPV45f 151 GTGGA AAAGT GCATT ACAGG
HPV45r ACCTC TGTGC GTTCC AATGT
Cocktail 2 HPV33f 398 ACTAT ACACAACATT GAACT A
HPV33r GTTTT TACAC GTCAC AGTGC A
HPV6_11f 334 TGCAA GAATG CACTG ACCAC
HPV6_11r TGCAT GTTGT CCAGC AGTGT
HPV58f 274 GTAAA GTGTG CTTAC GATTG C
HPV58r GTTGT TACAG GTTAC ACTTG T
HPV52f 229 TAAGG CTGCA GTGTG TGCAG
HPV52r CTAA TAGTT ATTTCA CTTAA TGGT
HPV56f 181 GTGTG CAGAG TATGT TTATT G
HPV56r TTTCT GTCAC AATGC AATTG C
Cocktail 3 HPV35f 358 CAACG AGGTA GAAGA AAGCA TC
HPV35r CCGAC CTGTC CACCG TCCAC CG
HPV42f 277 CCCAA AGTAG TGGTC CCAGT TA
HPV42r GATCT TTCGT AGTGT CGCAG TG
HPV43f 219 GCATA ATGTC TGCAC GTAGC TG
HPV43r CATGAAACTG TAGAC AGGCC AAG
HPV44f 163 TAAAC AGTTA TATGT AGTGT ACCG
HPV44r TATCA GCACG TCCAG AATTG AC
Cocktail 4 HPV68f 333 GCAGAAGGCA ACTAC AACGG
HPV68r GTTTA CTGGT CCAGC AGTGG
HPV39f 280 GACGACCACT ACAGC AAACC
HPV39r TTATG AAATC TTCGT TTGCT
HPV51f 223 GAGTA TAGAC GTTAT AGCAG G
HPV51r TTTCG TTACG TTGTC GTGTA CG
HPV66f 172 TTCAG TGTAT GGGGC AACAT
HPV66r AAACA TGACC CGGTC CATGC
F, f forward, r reverse, B back
Single letter code: W = A/T; K = G/T; R = A/G; Y = C/T; N = A/C/G/T; X = unknown. (Adapted from Soltar et al., [14])
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denaturation at 94 °C for 4 min was followed by 35 cycles
of denaturation at 94 °C for 30 s, annealing at 56 °C for
30 s, and an extension at 72 °C for 45 s. This was
followed by a single final extension at 72 °C of 4 min,
before a soaking step at 4 °C. For each round of PCR
reaction, HPV16 or/and HPV18 genome in plasmid
DNA as well as a sample positive for HPV used in the
optimisation of PCR were used as positive controls while
nuclease free water and DNA extracts form the non-
cancerous tissues was used as a negative control. A sample
each, found to be HPV negative or positive, were subse-
quently used as additional negative and positive control,
respectively.
Following the second round PCR, 8.0 μL of the prod-
ucts were resolved on a 2 % agarose gel stained with
0.001 mg/mL ethidium bromide. The electrophoresis
was carried out in 1X Tris Acetate EDTA (TAE) buffer
at 100 V for 1 h and the gel photographed over a UV
trans-illuminator. The molecular weights of the resolved
PCR products were used to determine the genotypes of
HPV detected for each sample according to the expected
weight for each primer (Table 1).
Statistical analysis
Data were managed and analysed with the Epi Info stat-
istical software, version 3.3 (CDC, Atlanta, USA). The
number and proportion of cases of carcinoma in situ
(CIS), invasive adenocarcinoma (IAC) and invasive squa-
mous cell carcinoma (ISCC) were determined. Further-
more, the number and proportions of detected HPV
genotypes, stratified by mode of infection (overall, single
and multiple infections), type of cervical cancer case and
age of the women were determined and presented in
frequency tables. The association between each HPV
genotype and multiple infection status was determined
by an analysis of odds ratio.
Results
After the hematoxylin and eosin staining of the second
10 μm section of each of the 342 paraffin embedded
formalin fixed cervical cancerous tissue blocks, 256 were
determined to have been adequate for PCR testing;
These consisted of 10 (3.9 %) cases of carcinoma in situ
(CIS), 19 (7.4 %) cases of invasive adenocarcinoma (IAC)
and 227 (88.7 %) cases of invasive squamous cell carcin-
oma (ISCC), as shown in Fig. 1.
HPV-specific DNA was detected in 230 samples
(Fig. 2), which is a prevalence of 89.8 % (95 % CI 85.7–
93.4 %). These positive samples were distributed among
the diagnosis categories as follows, 90.0 % (9 of 10)
Carcinoma in situ (CIS) cases, 89.5 % (17 of 19) invasive
adenocarcinoma (IAC) cases and 89.9 % (204 of 227)
invasive squamous cell carcinoma (ISCC). The four
commonly detected (overall prevalence) HPVs were
HPV18 (47.4 %), HPV59 (42.2 %), HPV45 (37.4 %) and
HPV16 (10.0 %) (Table 2). Single infections were ob-
served among 110 (47.8 %) of the 230 HPV DNA posi-
tive cases and the same four HPV genotypes were the
commonest single infecting genotypes but in a different
order. This was as follows, HPV45 (29.4 %), HPV18
(23.95 %), HPV59 (15.6 %) and HPV16 (9.2 %). Eight of
the single infections were solely of low-risk HPV types
(Table 2), these were; 4 ISCC cases with HPV44, 1 CIS
and 1 ISCC case with HPV6_11 and 2 ISCC cases with
HPV42. Multiple-infections occurred in 120 (52.2 %) of
the 230 DNA positive cases. Double infections were
observed in 90 (39.1 %), triple infection in 28 (12.0 %)
and quadruple infections in 5 (2.2 %) of the 230 HPV
positive cases (Table 3). Double infections involving
HPV18 were the commonest. Those with HPV18 and
HPV59 occurred in 30 (13.0 %) cases, those with HPV18
and HPV16 occurred in 3 (1.3 %) and those with HPV18
and HPV45 occurred in 2 (0.9 %) cases. Furthermore,
the commonest triple HPV infections were detected in
17 (7.3 %) cases and these involved HPV-18, -45 and
-59. All the other 9 triple infections were each detected
once while all the 5 quadruple infection involved HPV-
16, -18, -45 and -59 (Table 3).
An age stratified distributions of the data showed that
the age groups 40–59 years and 60–79 years carried the
highest burden of each diagnosis categories of cervical
cancer, overall HPV infection positivity, single and mul-
tiple HPV infections (Table 4). Specifically, 63.2, 60.0
Fig. 1 Distribution of diagnosed cervical cancer cases
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and 44.5 % of the IAC, CIS and ISSC cases were ob-
served among the age range of 40–59 years. Further-
more, 46.5 % of all HPV infections, 51.4 % of single
infections and 42.4 % of multiple infections (represent-
ing the highest proportion in category) were detected
among cases of this age range.
Specific genotype distributions among the diagnosis
categories were presented in Table 5. HPV16 was ob-
served in 3 (33.3 %) of the 9 CIS cases, 3 (15.8 %) of the
19 IAC cases and 17 (7.5 %) of the 227 ISCC cases.
HPV18 was observed in 3 (33.3 %) of the 9 CIS cases, 7
(36.8 %) of the 19 IAC cases and 99 (43.6 %) of the 227
Fig. 2 Detected type specific HPV DNA in multiple infections. Round 2 amplification products were resolved at 100 V for 1 h on a 2 % agarose
gel stained with 0.001 mg/mL of ethidium bromide and photographed under UV illumination. The HPVs were identified based on the molecular
weight of the amplification products for each are shown below the gel. Lane -ve⇒ HPV negative control; Lane MW⇒ Bands of the 100 base pair
molecular weight maker; Lane + ve⇒ HPV16 and HPV18 DNA positive control
Table 2 Distribution of specific HPV genotypes detected in cancerous cervical tissues, occurring either as single infections or
alongside others in multiple-infections
HPV type Overall, (%)a (N = 230) Multiple-infections (%)b (N = 120) Single infections (%)c (N = 110) Odds ratio (OR) 95 % CI
18 109 (47.4) 83 (68.6) 26 (23.9) 6.97d 3.89–12.50
59 97 (42.2) 80 (66.1) 17 (15.6) 10.56d 5.57–20.02
45 86 (37.4) 54 (44.6) 32 (29.4) 1.94d 1.12–3.35
16 23 (10.0) 13 (10.7) 10 (9.2) 1.19 0.50–2.84
31 20 (8.7) 14 (11.6) 6 (5.5) 2.50 0.83–6.07
56 14 (6.1) 9 (7.4) 5 (4.6) 1.67 0.54–5.15
6_11 10 (4.3) 6 (5.0) 2 (1.8) 1.40 0.37–1.99
35 8 (3.5) 6 (5.0) 2 (1.8) 2.79 0.55–14.13
42 7 (3.0) 4 (3.3) 2 (1.8) 1.21 0.26–5.52
44 7 (3.0) 3 (2.5) 4 (3.7) 0.66 0.15–3.05
58 5 (2.2) 3 (2.5) 2 (1.8) 1.36 0.22–8.30
33 3 (1.3) 3 (2.5) 0 (0.0) UD UD
66 2 (0.9) 1 (0.8) 1 (0.9) 0.90 0.06–14.57
43 1 (0.4) 1 (0.8) 0 (0.0) UD UD
51 1 (0.4) 0 (0.0) 1 (0.9) UD UD
UD undeterminable, as a result of less than five detections of each HPV for each state of infection
OR =Measures the odds of the association between being positive for each type HPV and the state of multiple-infection
apercentage of total infections
bpercentage of total multiple-infections
cpercentage of total single infections
dSignificantly associated with multiple-infections because odds ratio is not = 1.0 and a 95 % CI does not overlapping 1.0
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ISCC cases. HPV 6_11was observed in 2 (22.2 %) of
the 9 CIS cases, 8 of the 227 ISCC cases but was not
observed in IAC cases. Furthermore, Table 6 shows
the age distribution of the commonly detected HPV
genotype. The age groups 60–79 years harbored a
high proportion of HPV-18, 59 and 45 although the
age group 40–59 years harboured the highest overall
HPV infection (Table 4).
Discussion
As shown in Fig. 1, the observed distribution of cervical
cancer cases was in line with global observations re-
ported for the study period [16] and the age group with
the highest burden of cervical cancer in this study was
consistent with global data on cervical cancer (Table 4).
Similarly, the prevalence of HPV DNA (89.8 %, 95 % CI
85.7–93.4 %) among these cases of cervical cancer,
which was based on the amplification of the viral E6 and
E7 oncogenes, was comparable to that (89.4 %) reported
by a study of cervical tumour samples in the neighbour-
ing Cote d’Ivoire [17]. Additionally, a comparable HPV
prevalence of 93.9 % was reported among cases diag-
nosed as CIN II or higher in the study from which the
HPV detection and genotyping methods were adapted
[14]. However, in an earlier study of 50 similarly proc-
essed samples collected between January and December
2003 at the same hospital and using the same HPV
detection methods, an HPV positivity of 98.0 % was
reported [15]. Additionally, data reported for Ghana in a
multi-centre study, which used biopsy samples collected
between October 2007 and March 2010 and a different
HPV detection and genotyping methods, indicated an
overall HPV prevalence of 93.9 % [18]. In respect of the
genotype specific prevalence (Table 2), HPV18 was the
commonest genotype detected in this study as was the
case the earlier study in Ghana [15], however, HPV16
was the commonest for the Ghanaian data reported in
the multi-centre study [18].
Although these overall HPV prevalence were within
the expected range of 90–100 % [19] and that there are
Table 3 Distribution of multiple- and double infections involving
HPV-18 and the other most detected HPV genotypes
Multiple-infection Number (% of total HPV infections)
Double infections 90 (39.1)
HPV-18 and HPV-59 30
HPV 18 and HPV 31 4
HPV-18 and HPV-16 3
HPV-18 and HPV 45 2
Triple infections 25 (10.8)
HPV-18,-45 and -59 17
HPV-18,-31 and 6_11 1
HPV-18, -35 and -42 1
HPV-18, -35 and -58 1
HPV-18, -42 and -6_11 1
HPV -18, -45 and -56 1
HPV -18, -59 and -6_11 1
HPV -16, -18 and -31 1
HPV-16, -18 and -59 1
HPV-16, -42 and -66 1
HPV-31, -45 and 6_11 1
HPV-45, -56 and 6_11 1
Quadruple infections 5 (2.2)
HPV-16, -18, -45 and -59 5
Table 4 Age stratified distribution of histologic type and HPV infection among the cervical cancer cases
Age group
(years)
Histological type, n (%) HPV status, n (%) Type of Infection, n (%)
CIS IAC ISCC HPV (−) HPV (+) Multiple Single
20–39 1 (10.0) 1 (5.3) 17 (7.5) 4 (15.4) 15 (6.5) 7 (5.8) 8 (7.2)
40–59a 6 (60.0) 12 (63.2) 101 (44.5) 12 (46.2) 107 (46.5) 51 (42.5) 56 (50.9)
60–79 3 (30.0) 5 (26.3) 89 (39.2) 10 (38.5) 88 (38.3) 50 (41.6) 38 (34.5)
>79 0 (0.0) 0 (0.0) 18 (7.9) 0 (0.0) 18 (7.8) 10 (8.3) 8 (7.3)
- 0 (0.0) 0 (0.0) 2 (0.9) 0 (0.0) 2 (0.9) 2 (1.6) 0 (0.0)
Total 10 19 227 26 230 120 110
aAge group with significantly higher proportions of cases and HPV infection
Table 5 Distribution of the common HPV genotypes among
the types of cancers
HPV genotype Number (%)
CIS IAC ISCC
18 3 (30.0) 7 (36.8) 99 (43.6)
59 4 (40.0) 8 (42.1) 85 (37.4)
16 3 (30.0) 3 (15.8) 17 (7.5)
45 0 (0.0) 7 (36.8) 79 (34.8)
35 1 (9.0) 0 (0.0) 7 (3.1)
6_11 2 (20.0) 0 (0.0) 8 (3.5)
56 0 (0.0) 1 (5.3) y5.7)
Total tested 10 19 227
% are of the total of each type of cancer (because of multiple-infections, the
percentage may add up to more than 100)
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reports of within country variation in HPV genotype
specific prevalence [11], the differences between these
studies may have been influenced by the following facts.
The first is the difference in the type of specimen
used in these studies. Specifically, this and the study
by Attoh et al., [15] used archived formalin-fixed
paraffin-embedded tissue blocks while the study by
Denny et al., [18] used freshly collected biopsy sam-
ples. Also, the processing of the archived tissue blocks
used in this studyand that by Attoh et al., [15] were
not standardized and therefore different levels of in-
hibitors may have been present in the samples and in
extracted DNA. The second was that the cases in
these studies were received from different locations
across the country and therefore the differences in
prevalence may be a reflection of the inter-country varia-
tions. Thirdly, the variations in the times of samples
collection, without overlaps, (2003, 2004–2006 and 2007–
2010) and the relatively small number (n = 50) of samples
used in the study by Attoh et al., [15] may have contrib-
uted to the differences in the data of these studies.
Inrespect of the genotype specific prevalence, the high
prevalence of HPV59 and its frequency in multiple infec-
tions in this study remains unclear. However, the differ-
ences in these three studies most probably are a reflection
of the variability in the HPV prevalence in the Ghanaian
population and therefore there is the need for a well-
controlled randomized population based HPV prevalence
study in Ghana. On the other hand, a comparison of these
HPV distributions with those of Ghana’s neighbouring
populations strongly supports the existence of geograph-
ical difference in the prevalence of HPV genotypes and the
possibility that HPV16 may not be the most prevalent
genotype in these African countries. For instance, a study
in Benin reported HPV59 (24.6 %), HPV35 (22.5 %),
HPV16 (17.6 %), and HPV18 (14.8 %) as the common
HPV genotypes detected [15]. Also, a study in Cote
d’Ivoire reported HPV16 (45.0 %), HPV18 (21.0 %),
HPV45 (9.0 %), HPV35 (8.0 %), and HPV31 (3.0 %) as the
common genotypes [17] while in a study in Burkina Faso,
HPV52 (14.7 %), HPV35 (9.4 %), HPV58 (9.4 %), and
HPV51 (8.6 %) were the common genotypes [20]. Further-
more, study form other regions in and outside Africa
confirm the assertion that although HPV16 and HPV18
are the commonest HPVs in cervical cancers globally, they
are not always the two commonest HPVs in every country.
For instance, in Tanzania, HPV16 and HPV58 were the
first two prevalent genotypes while HPV18 was the fifth
[21]; In Mozambique, HPV35 was the most prevalent
HPV genotype while no HPV18 genotype was detected
among women diagnosed with HSIL or carcinoma [22].
Liaw et al., [23] reported HPV52 and HPV58 as the most
prevalent type in parts of China.
Interestingly, HPV18, HPV59 and HPV45, which are
of the same phylogenetic family [7], as expected were
the common genotypes in adenocarcinoma (Table 5).
On the other hand, HPV16 and its phylogenetic related
family members, HPV31 and HPV35 were respectively
the fourth, fifth and eighth prevalent HPV in this study.
Furthermore, most of the multiple-infections observed
in this study involved HPV18 and HPV59. These suggest
that a phylogenetic dependency in the colonization of
cervical epithelium might contribute to HPV prevalence,
as was observed by Conesa-Zamora et al., [24] for HPV18
and HPV45. Therefore, these may suggest a phylogenetic
related HPV prevalence in Ghana, although the bases for
such specificities are still not clear.
Although, the frequency of multiple-infections varies
with the type of HPV detection method used [25], the
52.2 % multiple-infections observed in this study as
compared to that of the earlier Ghanaian study, 19.6 %
[18], are discussed in light of the fact that most (about
96 %) of the cases in this study (Fig. 1) were invasive
cancers (IAC and ISSC) which are known to be associ-
ated with high multiple-infections [25]. Also, data from
neighbouring countries have shown similar high frequen-
cies of multiple-infections. A 52.9 % rate of multiple-
infection was observed in a study in Burkina Faso [20],
while a 40.2 % rate was reported by a in Benin [19]. These
may suggest a high rate of multiple-infection in the West
African region. However, these may be a population spe-
cific observation as was shown by two studies in Spain, a
25.6 % rate of multiple-infection among HSIL cases in
Southern Spain [24], while a 34.0 % was observed in a
cohort of women in Madrid [24, 26].
Since both cross-protection of the available HPV16/18
vaccines and its clinical relevance determined with the
data available for vaccine efficacy have shown additional
protection against HPVs -31, -33, -45, -51, -52, -56 and
Table 6 Distribution of the most frequent HPV genotype
infection among cervical cancer patient according to age









18 7 (46.7) 48 (44.9) 47 (53.4) 7 (38.8)
59 6 (40.0) 40 (37.4) 42 (47.7) 9 (50.0)
16 1 (6.6) 13 (12.1) 7 (8.0) 2 (11.1)
45 6 (40.0) 36 (33.6) 37 (42.0) 7 (38.8)
35 1 (6.6) 3 (2.8) 3 (3.4) 1 (5.5)
42 0 4 (3.7) 2 (2.3) 1 (5.3)
6_11 0 6 (5.6) 4 (4.5) 0 (0.0)
44 0 2 (1.9) 3 (3.4) 2 (11.0)
The number HPV risk types may add up to more than the total number of
cancer patients for each age group due to multiple-infection of some patients
or may be less than reported in Table 2 because some participants’ age was not
available. % are of the total number of HPV positive cases (presented as n) in
each age range
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-58 [27, 28], the expected impact of HPV vaccination on
cervical cancers in Ghana may be further increased.
Specifically, if the infection by HPV59 depends on a
prior infection by HPV18 [24] since they most oc-
curred together in this study, then a lower prevalence
of both HPV18, HPV 59 and lower frequency of mul-
tiple infection may result after the introduction of the
HPV16/18 vaccines.
Another finding worth commenting on was the obser-
vation that low risk HPV types (HPV-6/11, -42 and -44)
were solely detected as single infections in 8 cervical
cancer cases (1 CIS, 7 ISCC). These were least expected
and may be misleading in suggesting a higher oncogenic
potential for these low risk HPV types since low risk
type HPVs are rarely observed as single infections in
invasive cancers [7]. However, due to the limitation
associated with DNA extract and PCR using formalin-
embedded paraffin-embedded specimen (presence of
inhibitors from sample fixatives), it was possible that the
other multiple-infecting high risk HPV genotypes
present were not detected since DNA extracts from
paraffin-embedded formalin-fixed tissue samples have
been reported to intermittently fail to amplify by PCR
[29]. Specifically, because PCR inhibitors may have been
be present at varying concentrations, the concentration
of the target DNA and its quality may have been greatly
reduced after tissue processing and/or the target viruses
may have been heterogeneously distributed in the cancer-
ous tissues [29–31]. The limitation of this study includes
the fact that it was not powered to determine the as-
sociations between HPV genotypes and the diagnosis
categories of cervical cancer. Also, the HIV statuses
of the patients, which may influence HPV prevalence,
were not determined.
Conclusion
Overall, the findings of this study indicate a peculiar
HPV profile for Ghana, which has important implication
for the introduction of HPV vaccination and forms part
of a growing body of evidence of the pre-vaccination
HPV prevalence for Ghana. However, rigorous epidemi-
ologic data and well-controlled randomized trials are
needed in order to estimate the extent of protection or
prevention of cervical cancer that may be achieved with
the introduction of HPV vaccination in Ghana; particu-
larly in light of the high multiple-infection prevalence
observed in this study. These also underscore the need
for community based screening of women for both cer-
vical cancer and HPV infection, which should include
HPV genotype analysis as part of the screening schemes
for women with high-grade neoplasia and cervical can-
cer in Ghana. These will help throw more light on the
high rate of multiple-infections, particularly those in-
volving HPV59.
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